Cargando…
小檗碱联合硼替佐米对多发性骨髓瘤细胞株U266细胞作用机制的体外研究
OBJECTIVE: To investigate the effects of berberine in combination with bortezomib on proliferation and apoptosis of multiple myeloma (MM) cell line. METHODS: MM cell line U266 cells were treated with berberine and/or bortezomib. The effects of berberine and/or bortezomib on proliferation of cells we...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348517/ https://www.ncbi.nlm.nih.gov/pubmed/27995884 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.11.010 |
_version_ | 1783556845105840128 |
---|---|
collection | PubMed |
description | OBJECTIVE: To investigate the effects of berberine in combination with bortezomib on proliferation and apoptosis of multiple myeloma (MM) cell line. METHODS: MM cell line U266 cells were treated with berberine and/or bortezomib. The effects of berberine and/or bortezomib on proliferation of cells were measured by methylthiazolyl tetrazolium bromide (MTT). Flow cytometric Annexin Ⅴ/PI double staining method was used to detect effect of either drug alone or in combination on apoptosis of MM cell line U266. ELISA was used to measure the expression of casepase-3,-8,-9 affected by the two drugs. Western blot was used to detect the expression of the apoptosis-related protein TRADD and FADD. King formula was used to determine if there was a synergistic effect of berberine in combination with bortezomib. RESULTS: ①Both berberine and bortezomib as single agent had dose- and time-dependent effects of proliferation inhibition on U266 cells. Berberine (20 µmol/L) and bortezomib (5 nmol/L) had a synergistic effect of proliferation inhibition (Q value: 1.31–1.65). ②The proportion of early stage apoptosis in both single agent groups and combination group significantly increased compared to control group (P< 0.05). Berberine and bortezomib had a synergistic effect on cell apoptosis (Q value after 6 h and 12 h were 0.896 and 1.197, respectively). ③Berberine in combination with bortezomib significantly upregulated expressions of caspase-3, -8 and -9, which were statistically significant (P<0.05). ④Berberine in combination with bortezomib significantly upregulated expressions of TRADD (0.91±0.01, 0.70±0.01) and FADD (0.98±0.01, 0.98±0.01) compared with control group (both P<0.05). CONCLUSION: Berberine in combination with bortezomib had synergistic effects on proliferation inhibition and apoptosis, which were mediated by up-regulated levels of TRADD and FADD. |
format | Online Article Text |
id | pubmed-7348517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73485172020-07-16 小檗碱联合硼替佐米对多发性骨髓瘤细胞株U266细胞作用机制的体外研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the effects of berberine in combination with bortezomib on proliferation and apoptosis of multiple myeloma (MM) cell line. METHODS: MM cell line U266 cells were treated with berberine and/or bortezomib. The effects of berberine and/or bortezomib on proliferation of cells were measured by methylthiazolyl tetrazolium bromide (MTT). Flow cytometric Annexin Ⅴ/PI double staining method was used to detect effect of either drug alone or in combination on apoptosis of MM cell line U266. ELISA was used to measure the expression of casepase-3,-8,-9 affected by the two drugs. Western blot was used to detect the expression of the apoptosis-related protein TRADD and FADD. King formula was used to determine if there was a synergistic effect of berberine in combination with bortezomib. RESULTS: ①Both berberine and bortezomib as single agent had dose- and time-dependent effects of proliferation inhibition on U266 cells. Berberine (20 µmol/L) and bortezomib (5 nmol/L) had a synergistic effect of proliferation inhibition (Q value: 1.31–1.65). ②The proportion of early stage apoptosis in both single agent groups and combination group significantly increased compared to control group (P< 0.05). Berberine and bortezomib had a synergistic effect on cell apoptosis (Q value after 6 h and 12 h were 0.896 and 1.197, respectively). ③Berberine in combination with bortezomib significantly upregulated expressions of caspase-3, -8 and -9, which were statistically significant (P<0.05). ④Berberine in combination with bortezomib significantly upregulated expressions of TRADD (0.91±0.01, 0.70±0.01) and FADD (0.98±0.01, 0.98±0.01) compared with control group (both P<0.05). CONCLUSION: Berberine in combination with bortezomib had synergistic effects on proliferation inhibition and apoptosis, which were mediated by up-regulated levels of TRADD and FADD. Editorial office of Chinese Journal of Hematology 2016-11 /pmc/articles/PMC7348517/ /pubmed/27995884 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.11.010 Text en 2016年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 小檗碱联合硼替佐米对多发性骨髓瘤细胞株U266细胞作用机制的体外研究 |
title | 小檗碱联合硼替佐米对多发性骨髓瘤细胞株U266细胞作用机制的体外研究 |
title_full | 小檗碱联合硼替佐米对多发性骨髓瘤细胞株U266细胞作用机制的体外研究 |
title_fullStr | 小檗碱联合硼替佐米对多发性骨髓瘤细胞株U266细胞作用机制的体外研究 |
title_full_unstemmed | 小檗碱联合硼替佐米对多发性骨髓瘤细胞株U266细胞作用机制的体外研究 |
title_short | 小檗碱联合硼替佐米对多发性骨髓瘤细胞株U266细胞作用机制的体外研究 |
title_sort | 小檗碱联合硼替佐米对多发性骨髓瘤细胞株u266细胞作用机制的体外研究 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348517/ https://www.ncbi.nlm.nih.gov/pubmed/27995884 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.11.010 |
work_keys_str_mv | AT xiǎobòjiǎnliánhépéngtìzuǒmǐduìduōfāxìnggǔsuǐliúxìbāozhūu266xìbāozuòyòngjīzhìdetǐwàiyánjiū AT xiǎobòjiǎnliánhépéngtìzuǒmǐduìduōfāxìnggǔsuǐliúxìbāozhūu266xìbāozuòyòngjīzhìdetǐwàiyánjiū AT xiǎobòjiǎnliánhépéngtìzuǒmǐduìduōfāxìnggǔsuǐliúxìbāozhūu266xìbāozuòyòngjīzhìdetǐwàiyánjiū AT xiǎobòjiǎnliánhépéngtìzuǒmǐduìduōfāxìnggǔsuǐliúxìbāozhūu266xìbāozuòyòngjīzhìdetǐwàiyánjiū |